Boeing's Got a New Drone (Same as the Old Drone)

Boeing’s MQ-25A Stingray completed its first test flight after an eight-year wait, advancing a potential $15.9 billion Navy program. The Pentagon may begin low-rate initial production as early as this year, with carrier testing targeted for late 2026 and first operational deployment no earlier than 2029. The program could ultimately generate about $16 billion in revenue for Boeing, though delays and cost creep remain risks.

Analysis

This is less a near-term revenue story than a latency arbitrage on program completion: the market has had eight years to discount the contract, but the valuation gap only closes if Boeing can convert a paper win into production cadence without another schedule slip. The bigger second-order effect is on carrier air wing composition; every month the Navy delays this capability, it keeps a meaningful slice of high-value fighter hours tied up in tanker duty, which preserves utilization for legacy F/A-18 support ecosystems but delays a step-change in carrier strike efficiency.

The main beneficiary is Boeing defense cash flow, but the real upside is option-like: low-rate production plus follow-on sustainment can improve margin mix materially versus the first article's implied headline contract value. The risk is not cost overrun so much as bureaucratic drift—if carrier testing slips or mission reliability underperforms, the program can remain 'real' without becoming budget-relevant, which would defer both margin and sentiment re-rating by 12-24 months.

Competitively, this is mildly negative for any platform that would have competed for future unmanned naval aviation work, but the more interesting loser is the incumbent tanker role on carriers, which can reduce demand intensity for fighter utilization rather than aircraft count. A hidden positive for Boeing is that defense credibility is increasingly being judged on execution in an area where commercial operations cannot contaminate the narrative; a clean MQ-25 transition would partially offset broader skepticism around the franchise.

The contrarian view is that the stock may still be under-owned for defense optionality: investors are pricing Boeing as a commercial turnaround story, while defense is quietly becoming the cleaner earnings bridge. But the path is long enough that this is not a catalyst-trade; it is a multi-quarter monitoring position with asymmetric upside if the Navy authorizes production and the test program stays clean through carrier integration.

Key Decisions for Investors

• Long BA on a 6-12 month horizon as a defense-execution call, but size it as a catalyst option: upside improves materially if low-rate production is approved and carrier testing stays on track; cut if integration milestones slip into 2027.
• Pair trade: long BA / short NOC for the next 3-6 months if you want relative defense exposure with less dependence on platform procurement cycles; BA has more specific program optionality, while NOC is more exposed to broader budget timing.
• Buy BA call spreads expiring after the expected carrier-test window, targeting a move on production authorization; this limits downside if the Navy pushes deployment out again, while preserving upside if the program becomes budget-relevant.
• Avoid chasing the move in the next few weeks; the stock is likely to trade on headline momentum before fundamentals change. Best entry is on any pullback tied to schedule noise rather than on positive press alone.
• If the Navy confirms low-rate initial production, rotate into the defense supply chain names with upgrade exposure rather than prime contractor beta; the better second-order trade is on components and sustainment, not just BA equity.